科技圈🎗在花频道📮 | Telegram Webview: TestFlightCN/31945 -

科技圈🎗在花频道📮

过敏性鼻炎治疗研究取得新进展

2025年4月4日，首都医科大学附属北京同仁医院张罗教授团队在国际顶级期刊《自然·医学》（Nature Medicine）发表突破性研究成果——《司普奇拜单抗治疗中重度季节性过敏性鼻炎：一项随机3期试验》（Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial）。
这是全球范围内首次报告基于IL-4Rα靶点的生物制剂治疗季节性过敏性鼻炎的研究成果，亦是中国科学家在过敏性鼻炎领域取得的引领世界的创新性新成果。研究结果显示，司普奇拜单抗能够快速、强效控制患者的鼻部症状，持续显著缓解患者眼部过敏症状，极大提升患者生活质量，且安全性良好。

Nature Medicine

📮投稿 ☘️频道 🌸聊天

www.tg-me.com/vn/在花软件新闻投稿频道/com.TestFlightCN/31945

21.2K viewsApr 5 at 12:04

tg-me.com/TestFlightCN/31945

Create: 2025-04-05
Last Update: 2025-04-29 22:39:42

BY 科技圈🎗在花频道📮

Share with your friend now:
tg-me.com/TestFlightCN/31945

在花软件新闻投稿频道 Telegram | DID YOU KNOW?

Unlimited members in Telegram group now

Telegram has made it easier for its users to communicate, as it has introduced a feature that allows more than 200,000 users in a group chat. However, if the users in a group chat move past 200,000, it changes into "Broadcast Group", but the feature comes with a restriction. Groups with close to 200k members can be converted to a Broadcast Group that allows unlimited members. Only admins can post in Broadcast Groups, but everyone can read along and participate in group Voice Chats," Telegram added.

The S&P 500 slumped 1.8% on Monday and Tuesday, thanks to China Evergrande, the Chinese property company that looks like it is ready to default on its more-than $300 billion in debt. Cries of the next Lehman Brothers—or maybe the next Silverado?—echoed through the canyons of Wall Street as investors prepared for the worst.